

To,

Date: 14.11.2023

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001 BSE Scrip Code: 539287	2. National Stock Exchange of India Limited Exchange plaza, C-1, Block G, Bandra Kurla Complex, Bandra, East, Mumbai-400 051, Maharashtra NSE: ORTINLAB
--	--

Dear Sir/Madam,

Unit: Ortin Laboratories Limited

Sub: Outcome of Board Meeting held on 14.11.2023

Ref: Our Company's letter of advance intimation dated 06.11.2023

With reference to the subject cited, this is to inform the Exchanges that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Tuesday, 14.11.2023 at 4:00 p.m. at the registered office of the Company at D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street no. 3, Baghlingampally, Hyderabad — 500044, the following were considered and approved:

1. Unaudited financial results for the quarter and half-year ended 30.09.2023. (Enclosed)
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter and half-year ended 30.09.2023. (Enclosed).
3. Sale of the Undertaking/Total property of the Company including lands, buildings and machinery located at 275/278, Main Road, I.D.A. Pashamylaram, Sangareddy District, Telangana-502307, subject to the consent of the shareholders of the company under Section 180(1)(a) of the Companies Act, 2013, and

Further details in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed as Annexure A.

4. Convening Extra-Ordinary General Meeting of the Company on Thursday, December 14, 2023 at 11:00 AM through video conferencing/OAVM, for seeking approval of the members for the sale of whole or substantially the whole of the Undertaking.

The meeting which commenced at 4:00 p.m. concluded at 5:30 p.m.

This is for the information and records of the Exchanges.

Thanking you.

Yours sincerely,


For Ortin Laboratories Limited



S. Murali Krishna Murthy
Managing Director

DIN: 00540632

Encl: as above



Annexure A

Disclosure as per SEBI LODR Regulations:

Sale or disposal of unit(s) or division(s), whole or substantially the whole of the undertaking(s) or subsidiary of the listed entity, sale of stake in the associate company of the listed entity:

Sl.no	Particulars	Details
1.	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year 2022:23;	Rs.3,80,23,348.00 63.15%
2.	date on which the agreement for sale has been entered into	The Company proposes to enter into an agreement after obtaining necessary approvals including from members of the Company
3.	the expected date of completion of sale/disposal;	6 Months to 12 Months from the date of obtaining the approval from members
4.	consideration received from such sale/disposal;	NA
5.	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	The prospective buyer/parties will be identified after obtaining the approval of members.
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No
7.	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	No Scheme is applicable



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.23


Rupees In Lakhs

S No	Particulars	Quarter Ended	Preceeding Quarter Ended	Corresponding Quarter Ended in the Previous Year	Year to Date for Current Year Ended	Year to Date for Previous Year Ended	Previous Year Ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	a) Net Sales / Income from Operations	25.97	157.09	78.65	183.06	340.70	602.03
2	b) Other Operating Income	0.57	0.28	0.01	0.85	0.15	4.20
3	Total Income (1+2)	26.54	157.37	78.66	183.91	340.85	606.23
4	Expenditure						
	a) Cost of Material Consumed	-6.22	111.35	53.17	105.13	258.62	389.24
	b) Employee Benefits Expenses	22.12	19.16	22.16	41.28	43.70	84.66
	c) changes in inventory	45.00	-40.54	2.02	4.46	-11.26	-50.27
	d) Finance cost	15.04	11.42	8.52	26.46	18.04	39.64
	e) Depreciation	5.87	5.87	7.19	11.74	14.53	25.01
	d) Other Expenditure	55.27	48.55	23.99	103.82	52.35	126.33
	e) Total Expenses	137.08	155.81	117.05	292.89	375.98	614.61
5	Profit / (Loss) before Exceptional Items and tax (3-4)	-110.54	1.56	-38.39	-108.98	-35.13	-8.38
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	2.67
7	Profit / (Loss) before tax (5-6)	-110.54	1.56	-38.39	-108.98	-35.13	-11.05
8	Tax Expense						
	a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	b) Deferred Tax	1.54	-0.08	-46.47	1.46	-0.54	-1.69
9	Profit / (Loss) after tax for the period from continuing operations (7-8)	-112.08	1.64	8.08	-110.44	-34.59	-9.36
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	-112.08	1.64	8.08	-110.44	-34.59	-9.36
12	Paid-up equity share capital (Face value of Rs. 10/- per share)	813.14	813.14	813.14	813.14	813.14	813.14
13	Other Equity						273.35
14	Earnings Per Share (EPS)						
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(1.38)	0.02	0.10	(1.36)	(0.43)	(0.12)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(1.38)	0.02	0.10	(1.36)	(0.43)	(0.12)


Notes:

- The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14th November, 2023.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The figures for the quarter ended September 30, 2023 and September 30, 2022 are balancing figures between the un-audited figures in respect of the first quarter and year to date figures upto the second quarter for the respective periods which were subject to limited review.
- Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.
- The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.
- The Statutory Auditors of the Company have carried out "Review" of the above un-audited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The results are also available on the website of the Company www.ortinlabsindia.com

For and on Behalf of the Board of Directors
ORTIN LABORATORIES LIMITED



S.MURALI KRISHNA MURTHY
MANAGING DIRECTOR
(DIN: 00540632)




Place : Hyderabad
Date: 14.11.2023

Particulars	Standalone	
	As At 30th September, 2023 (Un-audited)	As At 31st March, 2023 (Audited)
I. ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	1,384.29	1,396.03
(b) Intangible Assets	-	-
(c) capital working progress	42.96	42.96
	1,427.25	1,438.99
(d) Financial Assets		
(i) Investments	-	-
(ii) Trade receivables	-	-
(iv) Others Financial Assets	23.50	27.07
(e) Deferred Tax Asset	-	-
(f) Long Term Loans and Advances	-	-
	23.50	27.07
(2) Current Assets		
(a) Inventories	249.04	259.84
(a) Financial Assets		
(i) Trade receivables	49.03	341.74
(ii) Cash and cash equivalents	31.66	21.98
(iii) Bank balances other than (ii) above	1.10	3.61
(iv) Loans and advances	-	-
(v) Other Financial Assets	-	-
(b) Current Tax Assets (Net)	-	-
(c) Other Current Assets	41.23	26.48
	372.05	653.65
Total Assets	1,822.80	2,119.71
II. EQUITY AND LIABILITIES:-		
EQUITY		
(a) Equity Share Capital	813.14	813.14
(b) Other Equity	162.91	273.35
	976.05	1,086.49
LIABILITIES		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	261.63	296.26
(b) Provisions	2.91	13.54
(c) Deferred Tax Liabilities	26.86	25.40
(d) non current liabilities	-	-
	291.40	335.20
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	339.40	348.41
(ii) Trade Payables	27.57	154.72
(iii) Other Financial Liabilities	-	-
(b) Other Current Liabilities	178.31	184.81
(c) Provisions	10.08	10.08
	555.36	698.02
Total Equity & Liabilities	1,822.80	2,119.71

For and on Behalf of the Board of Directors
ORTIN LABORATORIES LIMITED

S.MURALI KRISHNA MURTHY
MANAGING DIRECTOR
(DIN: 00540632)



Place : Hyderabad
Date: 14.11.2023


CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2023

Rupees In Lakhs

Particulars	30.09.2023 (Un-audited)	31.03.2023 (Audited)
Cash Flows from Operating Activities		
Net profit before tax	(108.98)	(11.05)
Adjustments for :		
Finance cost recognised in profit & loss	26.46	39.64
Depreciation	11.74	25.01
Profit /Loss on sale of Asset	-	(0.88)
Operating profit before working capital changes	(70.78)	52.72
Movements in Working Capital :		
(Increase)/Decrease in Trade and Other Receivables	292.71	(18.13)
(Increase)/Decrease in inventories	10.80	(85.74)
(Increase)/Decrease in Other financial assets	3.57	4.66
(Increase)/Decrease in Other assets	-	-
(Increase)/Decrease in Other Current Assets	(14.75)	(8.73)
Increase/(Decrease) in Trade Payables	(127.15)	75.98
Increase/(Decrease) in Other financial liabilities	-	-
Increase/(Decrease) in Other non current and Current liabilities	(6.50)	(46.09)
Increase/(Decrease) in Provisions	(10.63)	-
Changes in Working Capital	148.05	(78.05)
Cash generated from operations	77.27	(25.33)
Direct Taxes Paid	-	-
Net Cash from operating activities (A)	77.27	(25.33)
Cash flows from Investing Activities		
Purchase of Fixed Assets	-	0.82
changes in investments	-	-
Net Cash used in Investing Activities (B)	-	0.82
Cash flows from Financing Activities		
proceeds from issue of equity investments of company	-	-
Repayment/(Proceeds) of/from borrowings	(34.63)	123.33
Finance cost	(26.46)	(39.64)
Increase/decrease in short term borrowings	-	-
(Increase)/Decrease in Other bank balances	2.51	6.71
Net Cash used in Financing Activities (C)	(58.58)	90.40
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	18.69	65.89
Cash and Cash equivalents at the beginning of the year	(326.43)	(392.32)
Cash and Cash equivalents at the ending of the year	(307.74)	(326.43)
Particulars	30.09.2023	31.03.2023
Cash and Cash Equivalents	31.66	21.98
Less:Short Term Borrowings From Banks	(339.40)	(348.41)
	(307.74)	(326.43)

For and on Behalf of the Board of Directors
ORTIN LABORATORIES LIMITED

S. Murali Krishna Murthy
S.MURALI KRISHNA MURTHY
MANAGING DIRECTOR
(DIN: 00540632)



Place : Hyderabad
Date: 14.11.2023



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on unaudited quarterly and year to date financial results of the Company

**To The Board of Directors of
Ortin Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Laboratories Limited ("the Company") for the quarter ended on 30th September, 2023 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. *The Drugs Control Administration, Government of Telangana has cancelled the Manufacturing License of the Company vide their proceeding dated 03.07.2023 as the Company could not upgrade the manufacturing facilities, infrastructure and recruitment of expert technical team as per the provisions of Schedule - M of Drugs & Cosmetics Act 1940 & rules made there under. Hence the Company has stopped the production of medicines in its manufacturing unit. Our opinion is not modified in respect of this matter.*
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

K. MATHESH REDDY
M. No: 026285 Partner

Place: Hyderabad

Date: 14.11.2023

UDIN: 23026285BGXNHN4420

E-mail : mateshca@yahoo.co.in